Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | July 08, 2024 | July 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date July 08, 2024 · Filed July 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,978 |
Reported balance
After 2024-07-08 transaction · row 1
1 source rowRow 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 69,978 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2024 Filed Jul 10, 2024 23:49 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-031632 · wk-form4_1720655363.xml · nonDerivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,978 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 23:33 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 9,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-003132 · wk-form4_1706916810.xml · derivative · entry 2 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 23:33 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 9,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-003132 · wk-form4_1706916810.xml · nonDerivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 19:30 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 18,182 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-020843 · wk-form4_1685993416.xml · nonDerivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,424 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date). Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 23:12 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 9,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020584 · wk-form4_1685661153.xml · derivative · entry 2 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023. F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 23:12 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 9,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-020584 · wk-form4_1685661153.xml · nonDerivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: The restricted stock units vested on May 31, 2023. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:29 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantRestricted Stock Unit · Derivative | 9,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-002095 · wf-form4_167537696898838.xml · derivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,554 Underlying: Common Stock · 9,554 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:26 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 2,768 | $7.00 | $19,376.00 |
DisclosureSEC source: 0001628280-23-001478 · wf-form4_167459556288769.xml · derivative · entry 2 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on January 20, 2022. F3 · derivative.exercise_date: The restricted stock units vested on January 20, 2023. F3 · derivative.expiration_date: The restricted stock units vested on January 20, 2023. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:26 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 2,768 | $7.00 | $19,376.00 |
DisclosureSEC source: 0001628280-23-001478 · wf-form4_167459556288769.xml · nonDerivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,768 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRestricted Stock Unit · Derivative | 9,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-015997 · wf-form4_165418793024929.xml · derivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| January 20, 2022 Filed Jan 25, 2022 00:11 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRestricted Stock Unit · Derivative | 2,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000288 · primary_01.xml · derivative · entry 1 Diradoorian Raymond H · CIK 0001352121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,768 Underlying: Common Stock · 2,768 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.